In Brief: SmithKline Beecham's Tagamet HB
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham's Tagamet HB: OTC version of cimetidine is "approvable" at FDA as of June 13. The milestone moves Tagamet closer to becoming the second H2 antagonist approved for OTC use. J&J-Merck's Pepcid AC cleared FDA in April and entered the market in early June. Tagamet HB was recommended for approval by an FDA advisory committee in March. Approval is expected imminently...
You may also be interested in...
For Successful OTC Switch Proposals, A Good Offense Defends Against Doubters
OTC switch sponsors should identify adversaries early in the application switch process so they can counter arguments that could derail their switch, s consultant advises. Some switches fail because firms target regulatory approval and do little on marketplace performance.
For Successful OTC Switch Proposals, A Good Offense Defends Against Doubters
OTC switch sponsors should identify adversaries early in the application switch process so they can counter arguments that could derail their switch, s consultant advises. Some switches fail because firms target regulatory approval and do little on marketplace performance.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC